Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

therapeutics

9 posts
NNovartis
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape
Read More

Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape

  • 2026-07-14
Company Logo Opportunities include integrating cardio-renal strategies, aligning therapies with real-world evidence, leveraging site-of-care economics, and enhancing supply…
NNovartis
Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics
Read More

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

  • 2026-07-06
MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) — Brandon Capital, Australasia’s leading life sciences venture capital firm, today…
NNovartis
Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal
Read More

Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal

  • 2026-06-24
Just a year after spinning out from Scorpion Therapeutics, Antares Therapeutics has secured a big pharma partner to…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-08
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche’s…
NNovartis
Novartis Acquires Pikavation for Up to $3B, Expanding Cancer Pipeline
Read More

Novartis Acquires Pikavation for Up to $3B, Expanding Cancer Pipeline

  • 2026-06-04
Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics…
AAlps
Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer
Read More

Alps Group Inc Announces Potential Pipeline Expansion

  • 2026-04-06
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the “Company” or “Alps Group”), the…
RRoche
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Read More

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

  • 2026-03-16
With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI…
NNovartis
Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership
Read More

Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership

  • 2026-02-18
Novartis will apply Unnatural Products (UNP)’s artificial intelligence (AI)-guided macrocyclic peptide platform to develop next-generation cardiovascular disease therapeutics,…
NNovartis
What's next in Neuroscience drug discovery
Read More

What’s next in Neuroscience drug discovery

  • 2026-02-16
Bryan Laffitte has had a long career at Novartis in San Diego, California—with some twists and turns. After…
Switzerland
www.europesays.com